No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AIM AIM ImmunoTech
- 0.4346
- +0.0091+2.14%
Trading Apr 24 15:31 ET
22.06MMarket Cap-724P/E (TTM)
0.4600High0.4300Low119.17KVolume0.4420Open0.4255Pre Close52.26KTurnover0.26%Turnover RatioLossP/E (Static)50.75MShares0.748752wk High2.31P/B20.11MFloat Cap0.320152wk Low--Dividend TTM46.27MShs Float836.0000Historical High--Div YieldTTM7.05%Amplitude0.2910Historical Low0.4380Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | AIM ImmunoTech Inc - Files Prospectus Relates to Offer & Resale of up to 9.97 Mln Shares of Common Stock by Selling Stockholder
Analytical Instrument Management Acquires PSI Laboratories
LITTLETON, Colo., April 18, 2024 /PRNewswire/ -- Analytical Instrument Management (AIM) proudly announces its acquisition of PSI Laboratories, a well-established full-service analytical laboratory ba
Express News | AIM ImmunoTech Announces Charles Lapp, Md, as a Consulting Medical Officer for Its Me/Cfs and Long Covid Programs
Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 11, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO
Express News | AIM ImmunoTech Announces Top-Line, Protocol-Planned Interim Report Data From Study Of Ampligen Combined With Pembrolizumab For Recurrent Ovarian Cancer
Comments
$AIM ImmunoTech(AIM.US$
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
2
Update
$AIM ImmunoTech(AIM.US$ AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
3
Update
$AIM ImmunoTech(AIM.US$ AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions 2 MINUTES AGO, 8:50 AM EST VIA GLOBENEWSWIRE
1
Update
$AIM ImmunoTech(AIM.US$ AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer 3 MINUTES AGO, 9:10 AM EST VIA GLOBENEWSWIRE
Update
$AIM ImmunoTech(AIM.US$ AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg